<> <http://www.w3.org/2000/01/rdf-schema#comment> "The repository administrator has not yet configured an RDF license."^^<http://www.w3.org/2001/XMLSchema#string> .
<> <http://xmlns.com/foaf/0.1/primaryTopic> <https://discovery.ucl.ac.uk/id/eprint/10206194> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/ontology/bibo/AcademicArticle> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/ontology/bibo/Article> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/terms/title> "Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/terms/date> "2025-03-15" .
<https://discovery.ucl.ac.uk/id/document/1839188> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/ontology/bibo/Document> .
<https://discovery.ucl.ac.uk/id/org/ext-464ff5f0fac4572c5372d3e7fc978be1> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://xmlns.com/foaf/0.1/Organization> .
<https://discovery.ucl.ac.uk/id/org/ext-464ff5f0fac4572c5372d3e7fc978be1> <http://xmlns.com/foaf/0.1/name> "Elsevier BV"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/terms/publisher> <https://discovery.ucl.ac.uk/id/org/ext-464ff5f0fac4572c5372d3e7fc978be1> .
<https://discovery.ucl.ac.uk/id/publication/ext-26665247> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/ontology/bibo/Collection> .
<https://discovery.ucl.ac.uk/id/publication/ext-26665247> <http://xmlns.com/foaf/0.1/name> "The Lancet Microbe"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/terms/isPartOf> <https://discovery.ucl.ac.uk/id/publication/ext-26665247> .
<https://discovery.ucl.ac.uk/id/publication/ext-26665247> <http://www.w3.org/2002/07/owl#sameAs> <urn:issn:26665247> .
<https://discovery.ucl.ac.uk/id/publication/ext-26665247> <http://purl.org/ontology/bibo/issn> "26665247" .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/ontology/bibo/status> <http://purl.org/ontology/bibo/status/forthcoming> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/terms/creator> <https://discovery.ucl.ac.uk/id/person/ext-8292efcdc85f2259253447435ac7c8c1> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/ontology/bibo/authorList> <https://discovery.ucl.ac.uk/id/eprint/10206194#authors> .
<https://discovery.ucl.ac.uk/id/eprint/10206194#authors> <http://www.w3.org/1999/02/22-rdf-syntax-ns#_1> <https://discovery.ucl.ac.uk/id/person/ext-8292efcdc85f2259253447435ac7c8c1> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/terms/creator> <https://discovery.ucl.ac.uk/id/person/ext-0460eef8491f2a99694b09d0b8325d30> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/ontology/bibo/authorList> <https://discovery.ucl.ac.uk/id/eprint/10206194#authors> .
<https://discovery.ucl.ac.uk/id/eprint/10206194#authors> <http://www.w3.org/1999/02/22-rdf-syntax-ns#_2> <https://discovery.ucl.ac.uk/id/person/ext-0460eef8491f2a99694b09d0b8325d30> .
<https://discovery.ucl.ac.uk/id/person/ext-8292efcdc85f2259253447435ac7c8c1> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://xmlns.com/foaf/0.1/Person> .
<https://discovery.ucl.ac.uk/id/person/ext-8292efcdc85f2259253447435ac7c8c1> <http://xmlns.com/foaf/0.1/givenName> "Tom A"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/person/ext-8292efcdc85f2259253447435ac7c8c1> <http://xmlns.com/foaf/0.1/familyName> "Yates"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/person/ext-8292efcdc85f2259253447435ac7c8c1> <http://xmlns.com/foaf/0.1/name> "Tom A Yates"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/person/ext-0460eef8491f2a99694b09d0b8325d30> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://xmlns.com/foaf/0.1/Person> .
<https://discovery.ucl.ac.uk/id/person/ext-0460eef8491f2a99694b09d0b8325d30> <http://xmlns.com/foaf/0.1/givenName> "Daniel J"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/person/ext-0460eef8491f2a99694b09d0b8325d30> <http://xmlns.com/foaf/0.1/familyName> "Grint"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/person/ext-0460eef8491f2a99694b09d0b8325d30> <http://xmlns.com/foaf/0.1/name> "Daniel J Grint"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/EPrint> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/ArticleEPrint> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/terms/isPartOf> <https://discovery.ucl.ac.uk/id/repository> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://eprints.org/ontology/hasDocument> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839188> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/Document> .
<https://discovery.ucl.ac.uk/id/document/1839188> <http://www.w3.org/2000/01/rdf-schema#label> "Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes (PDF)"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://purl.org/dc/elements/1.1/hasVersion> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://eprints.org/ontology/hasPublished> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839188> <http://eprints.org/ontology/hasFile> <https://discovery.ucl.ac.uk/id/eprint/10206194/1/Yates%20and%20Grint%20-%20microbiological%20outcomes%20in%20TB%20trials.pdf> .
<https://discovery.ucl.ac.uk/id/document/1839188> <http://purl.org/dc/terms/hasPart> <https://discovery.ucl.ac.uk/id/eprint/10206194/1/Yates%20and%20Grint%20-%20microbiological%20outcomes%20in%20TB%20trials.pdf> .
<https://discovery.ucl.ac.uk/id/eprint/10206194/1/Yates%20and%20Grint%20-%20microbiological%20outcomes%20in%20TB%20trials.pdf> <http://www.w3.org/2000/01/rdf-schema#label> "Yates and Grint - microbiological outcomes in TB trials.pdf"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://eprints.org/ontology/hasDocument> <https://discovery.ucl.ac.uk/id/document/1839189> .
<https://discovery.ucl.ac.uk/id/document/1839189> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/Document> .
<https://discovery.ucl.ac.uk/id/document/1839189> <http://www.w3.org/2000/01/rdf-schema#label> "Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes (Other)"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/document/1839189> <http://eprints.org/relation/isVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839189> <http://eprints.org/relation/isVolatileVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839189> <http://eprints.org/relation/isIndexCodesVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839189> <http://eprints.org/ontology/hasFile> <https://discovery.ucl.ac.uk/id/eprint/10206194/2/indexcodes.txt> .
<https://discovery.ucl.ac.uk/id/document/1839189> <http://purl.org/dc/terms/hasPart> <https://discovery.ucl.ac.uk/id/eprint/10206194/2/indexcodes.txt> .
<https://discovery.ucl.ac.uk/id/eprint/10206194/2/indexcodes.txt> <http://www.w3.org/2000/01/rdf-schema#label> "indexcodes.txt"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://eprints.org/ontology/hasDocument> <https://discovery.ucl.ac.uk/id/document/1839190> .
<https://discovery.ucl.ac.uk/id/document/1839190> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/Document> .
<https://discovery.ucl.ac.uk/id/document/1839190> <http://www.w3.org/2000/01/rdf-schema#label> "Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes (Other)"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/document/1839190> <http://eprints.org/relation/isVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839190> <http://eprints.org/relation/isVolatileVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839190> <http://eprints.org/relation/islightboxThumbnailVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839190> <http://eprints.org/ontology/hasFile> <https://discovery.ucl.ac.uk/id/eprint/10206194/3/lightbox.jpg> .
<https://discovery.ucl.ac.uk/id/document/1839190> <http://purl.org/dc/terms/hasPart> <https://discovery.ucl.ac.uk/id/eprint/10206194/3/lightbox.jpg> .
<https://discovery.ucl.ac.uk/id/eprint/10206194/3/lightbox.jpg> <http://www.w3.org/2000/01/rdf-schema#label> "lightbox.jpg"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://eprints.org/ontology/hasDocument> <https://discovery.ucl.ac.uk/id/document/1839191> .
<https://discovery.ucl.ac.uk/id/document/1839191> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/Document> .
<https://discovery.ucl.ac.uk/id/document/1839191> <http://www.w3.org/2000/01/rdf-schema#label> "Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes (Other)"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/document/1839191> <http://eprints.org/relation/isVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839191> <http://eprints.org/relation/isVolatileVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839191> <http://eprints.org/relation/ispreviewThumbnailVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839191> <http://eprints.org/ontology/hasFile> <https://discovery.ucl.ac.uk/id/eprint/10206194/4/preview.jpg> .
<https://discovery.ucl.ac.uk/id/document/1839191> <http://purl.org/dc/terms/hasPart> <https://discovery.ucl.ac.uk/id/eprint/10206194/4/preview.jpg> .
<https://discovery.ucl.ac.uk/id/eprint/10206194/4/preview.jpg> <http://www.w3.org/2000/01/rdf-schema#label> "preview.jpg"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://eprints.org/ontology/hasDocument> <https://discovery.ucl.ac.uk/id/document/1839192> .
<https://discovery.ucl.ac.uk/id/document/1839192> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/Document> .
<https://discovery.ucl.ac.uk/id/document/1839192> <http://www.w3.org/2000/01/rdf-schema#label> "Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes (Other)"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/document/1839192> <http://eprints.org/relation/isVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839192> <http://eprints.org/relation/isVolatileVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839192> <http://eprints.org/relation/ismediumThumbnailVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839192> <http://eprints.org/ontology/hasFile> <https://discovery.ucl.ac.uk/id/eprint/10206194/5/medium.jpg> .
<https://discovery.ucl.ac.uk/id/document/1839192> <http://purl.org/dc/terms/hasPart> <https://discovery.ucl.ac.uk/id/eprint/10206194/5/medium.jpg> .
<https://discovery.ucl.ac.uk/id/eprint/10206194/5/medium.jpg> <http://www.w3.org/2000/01/rdf-schema#label> "medium.jpg"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://eprints.org/ontology/hasDocument> <https://discovery.ucl.ac.uk/id/document/1839193> .
<https://discovery.ucl.ac.uk/id/document/1839193> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/Document> .
<https://discovery.ucl.ac.uk/id/document/1839193> <http://www.w3.org/2000/01/rdf-schema#label> "Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes (Other)"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/document/1839193> <http://eprints.org/relation/isVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839193> <http://eprints.org/relation/isVolatileVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839193> <http://eprints.org/relation/issmallThumbnailVersionOf> <https://discovery.ucl.ac.uk/id/document/1839188> .
<https://discovery.ucl.ac.uk/id/document/1839193> <http://eprints.org/ontology/hasFile> <https://discovery.ucl.ac.uk/id/eprint/10206194/6/small.jpg> .
<https://discovery.ucl.ac.uk/id/document/1839193> <http://purl.org/dc/terms/hasPart> <https://discovery.ucl.ac.uk/id/eprint/10206194/6/small.jpg> .
<https://discovery.ucl.ac.uk/id/eprint/10206194/6/small.jpg> <http://www.w3.org/2000/01/rdf-schema#label> "small.jpg"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://discovery.ucl.ac.uk/id/eprint/10206194> <http://www.w3.org/2000/01/rdf-schema#seeAlso> <https://discovery.ucl.ac.uk/id/eprint/10206194/> .
<https://discovery.ucl.ac.uk/id/eprint/10206194/> <http://purl.org/dc/elements/1.1/title> "HTML Summary of #10206194 \n\nPrimary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes\n\n" .
<https://discovery.ucl.ac.uk/id/eprint/10206194/> <http://purl.org/dc/elements/1.1/format> "text/html" .
<https://discovery.ucl.ac.uk/id/eprint/10206194/> <http://xmlns.com/foaf/0.1/primaryTopic> <https://discovery.ucl.ac.uk/id/eprint/10206194> .